AstraZeneca Elevates Heart, Kidney Business in $1.8 Billion Deal with CinCor

AstraZeneca (AZN.L) said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc (CINC.O) for up to $1.8 billion to increase its stock of heart and kidney drugs.

Core to the deal is CinCor’s experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease.

AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease.

Read the source article at reuters.com